GARD is a pan-cancer predictor of clinical outcome in radiation treated patients.

Jacob G. Scott[1,2,3,4,†,*], **Geoffrey Sedor**[4,†], **Patrick Ellsworth**[4], **Jessica A. Scarborough**[1,3,4], **Kamran Ahmed**[5], **Steven A. Eschrich**[6], **Javier F. Torres-Roca**[5,*], **and Michael W. Kattan**[7,*]

[1]Translational Hematology and Oncology Research, Cleveland Clinic, Cleveland, OH
[2]Radiation Oncology Department, Cleveland Clinic, Cleveland, OH
[3]Systems Biology and Bioinformatics, School of Medicine, Case Western Reserve University, Cleveland, OH
[4]School of Medicine, Case Western Reserve University, Cleveland, OH
[5]Department of Radiation Oncology, Moffitt Cancer Center, Tampa, FL
[6]Department of Biostatistics and Biomedical Informatics, Moffitt Cancer Center, Tampa, FL
[7]Department of Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH
[*]scottj10@ccf.org, javier.torresroca@moffitt.org, kattanm@ccf.org
[†]contributed equally

ABSTRACT

Purpose/Objectives: Despite advances in cancer genomics, radiation therapy (RT) is still prescribed based on an empiric one-size-fits-all paradigm. Previously, we proposed a novel algorithm using the genomic adjusted radiation dose (GARD) to personalize RT prescription dose based on the biological effect of a given physical dose, calculated using individual tumor genomics. To validate the GARD-based RT dosing paradigm, we performed a pooled pan-cancer analysis in 9 separate clinical cohorts.

Materials/Methods: We collected 9 previously-published datasets for which all information to calculate GARD was available. Two clinical endpoints were defined: 1. time to any recurrence and 2. overall survival. The recurrence and survival analysis, included a total of 1098 (895 +RT, 203 -RT) and 821 patients (517 +RT, 304 -RT), respectively. A stratified Cox proportional hazard regression analysis was performed. A model was constructed in each disease site using GARD as the covariate and a common GARD effect was estimated.

Results: GARD is a continuous pan-cancer predictor of both recurrence and overall survival in patients treated with RT (any recurrence: coefficient =-0.019, $\chi-$square=8.9, p =0.003; overall survival: coefficient =-0.015, $\chi-$square=4.5, p =0.034), and was not predictive in those not treated with RT (any recurrence: coefficient =-0.033, $\chi-$square=1.3, p =0.247; overall survival: coefficient =0.016, $\chi-$square=2.1, p =0.148).

Conclusions: GARD is significantly associated with recurrence and survival in a continuous manner for the subset of patients receiving RT. We propose that a GARD-based framework should be adopted as the new paradigm for personalizing RT dose.

Introduction

Radiation therapy (RT) is the single most utilized therapy in oncology and is responsible for nearly half of all cancer cures. While the sequencing of the human genome changed the therapeutic paradigm in medical oncology, the same is not yet true for radiation oncology, where an empiric paradigm is still utilized to prescribe one-size-fits-all RT dosing: that is, all patients with a given cancer type receive the same prescription RT dose.

The clinical heterogeneity of radiation response, even within disease groups, is well established. Further, that this heterogeneity is at least partly driven and influenced by changes in the tumor genome is now accepted – indeed, large-scale classification efforts have been performed to understand these differences.[1–3] There have also been several efforts to understand surrogate genomic metrics for individual patient's resistance to radiation[4], as well as imaging-based studies.[5] None of these efforts, however, considers the explicit relationship between intrinsic tumor genomics and RT dose – the most fundamental parameter in radiation therapy.

We previously introduced the gene expression-based radiosensitivity index (RSI), a biomarker of tumor radiosensitivity, which we, and others, have validated in multiple individual cohorts, spanning various disease sites, by dichotomizing patients as either radiosensitive or radioresistant.[6,76,8–19] Subsequently, we developed the Genomic Adjusted Radiation Dose (GARD), which integrates RSI and RT dose to measure the biological effect of a given physical dose of RT.[15,20] This created the first opportunity to understand the relationship between intrinsic tumor radiation sensitivity and the biological effect of a given RT dose. Further, GARD allows a clinician to dose a patient's tumor to a desired biological radiation effect, rather than a physical dose, permitting personalization of RT dose based on tumor genomics: a new RT dose prescription paradigm.

To validate the GARD-based RT dosing paradigm, we performed a pooled pan-cancer analysis to compare disparate outcomes and disease sites in which we utilize all available clinical datasets with enough information to calculate GARD.[21]. In this manuscript, we analyze the predictive efficacy of GARD for recurrence and survival across 6 disease sites, encompassed by 9 separate cohorts, totaling more than 1,000 patients treated with or without RT.

Material and Methods

Clinical Cohorts and Endpoints

We collected a series of 9 previously-published datasets for which we had all information to calculate GARD (gene expression via Affymetrix microarray, total radiation dose and dose per fraction) and clinical outcome. GARD was calculated as previously reported, scaling RSI within each cohort.[15] These cohorts, which are summarized in Table 1, include patients treated with radiation for breast cancer (BC), including triple negative breast cancer (TNBC)[12,13,22], glioma[8], pancreatic[14], endometrial (EC)[19], head and neck[6] (HNC) and non-small cell lung[15] cancers (NSCLC). In addition, it includes patients that were not treated with RT as a negative control.

We defined two clinical endpoints: time to any recurrence and overall survival. Time to any recurrence included time to local, loco-regional and distant metastasis. Combining all clinical cohorts, we report the results of two independent analyses

of recurrence and survival endpoints separately. For the recurrence analysis, the pooled cohort includes a total of 1098 (895 +XRT, 203 -XRT) patients to analyze, with 300 events (281 +XRT, 19 -XRT). The survival analysis included 821 patients (517 +XRT, 304 -XRT) with 408 events (285 +XRT, 123 -XRT). Basic descriptive statistics for the clinical cohorts can be seen in Supplementary Tables 2 and 3. Individual disease sites were analyzed with Cox proportional hazards models. The pooled analysis was analyzed with a stratified Cox proportional hazards model, and a χ-squared statistic calculated using the Wald test.

Table 1. Cohorts included in the recurrence and survival pooled analysis. All available cohorts which had RSI, radiation dosing and clinical (recurrence and/or survival) outcomes information were included in the analysis.

Disease site	No. of patients	No. of events	Description and reference
		Recurrence Cohorts	
Breast	629	202	adjuvant RT for BC[12,13]
TNBC	113	29	adjuvant RT for TNBC[22]
Endometrium	204	18	adjuvant RT for EC[19]
Head and Neck	92	28	concurrent chemoradiation for HNC[7]
NSCLC	60	23	adjuvant RT for NSCLC[15]
Total	1098	300	
		Survival Cohorts	
Breast	159	40	adjuvant RT for BC[12,13]
TNBC	55	9	adjuvant RT for TNBC[22]
Endometrium	204	62	adjuvant RT for EC[19]
Glioma	270	209	concurrent chemoradiation (temozolomide) for glioma[8]
NSCLC	60	38	adjuvant RT for NSCLC[15]
Pancreas	73	50	adjuvant RT for pancreas[14]
Total	821	408	

Pooled Analysis Method

In order to statistically compare cohorts which are heterogeneous in outcome and disease type, we used a stratified Cox proportional hazards regression model. A model was constructed in each case using GARD as the covariate. This allowed each disease site to have a different baseline hazard function, yet still determine a common GARD effect. In addition, separate models were evaluated for those patients that did not receive RT. To calculate GARD for patients that did not receive RT, we assumed that they all received standard of care dose sham RT (50 Gy in 25 fractions for breast, 50 Gy in 25 fractions for pancreas, 60 Gy in 30 fractions for glioma, 54 Gy in 27 fractions for endometrium).

Results

GARD is a pan-cancer predictor of clinical outcome in RT-treated patients

To determine whether GARD is a pan-cancer predictor of clinical outcome in RT-treated patients, we performed Cox regression analysis for each disease cohort. In Table 1 we show the individual 5-year log proportional hazard with recurrence of any type and overall survival as the outcome. In Figure 1, we show a forest plot demonstrating the impact of GARD on any recurrence and survival endpoints in each of the individual cohorts studied. Patients treated with RT show a positive association between

each unit increase in GARD and improved outcome. As a negative control, we performed the same analyses in patients treated without RT (GARD calculated using standard of care dose sham radiation) which showed no association between GARD and either any recurrence or overall survival. In Figure 2, we demonstrate the results of the combined analysis of all cohorts. Pooled



Figure 1. Individual Cox proportional hazard ratios for each disease site and outcome type. Each site was fit to a unique Cox proportional hazard function using GARD, for patients that received radiation (top panel, +RT) and those that did not (bottom panel, -RT) in order to quantify the impact of each cohort on the final analysis. Recurrence (dotted) and survival (solid) were used as the outcome of interest for all disease sites. Each point represents the hazard ratio per unit GARD with horizontal lines showing 95% CI. In both subplots, values to the left of the intercept HR = 1 favor a predictive correlation with outcome of interest.

analysis of all available data reveal that GARD is a continuous predictor of recurrence (left, coefficient =-0.019, *chi*-square =8.9, p =0.003) and survival (right, coefficient =-0.015, *chi*-square =4.5, p =0.034). Recurrence pool for patients treated with RT (+RT) consisted of 895 patients at risk in 5 separate cohorts with 281 events, and survival pool consisted of 517 patients at risk in 6 cohorts with 285 events. GARD was not predictive for in patients who did not receive RT (any recurrence: coefficient =-0.033, $\chi-$square=1.3, p =0.247; overall survival: coefficient =0.016, $\chi-$square=2.1, p =0.148). Recurrence pool for patients not treated with RT (-RT) consisted of 203 patients at risk in 2 separate cohorts with 19 events, and survival pool consisted of 304 patients at risk in 4 cohorts with 123 events.



Figure 2. GARD is a statistically significant, continuous predictive biomarker of recurrence and survival in radiation treated patients. A stratified Cox proportional hazard model of all available data reveal that GARD is a continuous predictor of recurrence (left, coefficient =-0.019, *chi*-square =8.9, p =0.003) and survival (right, coefficient =-0.015, *chi*-square =4.5, p =0.034). Recurrence pool for patients treated with RT (+RT) consisted of 895 patients at risk in 5 separate cohorts with 281 events, and survival pool consisted of 517 patients at risk in 6 cohorts with 285 events. GARD was not predictive for in patients who did not receive RT (any recurrence: coefficient =-0.033, $\chi-$square=1.3, p =0.247; overall survival: coefficient =0.016, $\chi-$square=2.1, p =0.148). Recurrence pool for patients not treated with RT (-RT) consisted of 203 patients at risk in 2 separate cohorts with 19 events, and survival pool consisted of 304 patients at risk in 4 cohorts with 123 events.

Discussion

Radiation therapy is the single most commonly utilized anti-cancer therapy and is currently prescribed based on an empiric, one-size-fits-all paradigm. In this paper we show that GARD, a measure of biological radiation effect, is a statistically significant pan-cancer predictor of recurrence and survival in RT treated patients. We utilized all available clinical data, totalling over 1,000 patients, spanning 6 disease sites. To our knowledge, this is the first genomic pan-cancer predictor specific for RT-treated patients that is continuous with RT dose. A paradigm driven by GARD defines an actionable measure of biological effect of RT in a given patient. This permits a reframing of our thinking, enabling us to modulate and personalize the biological effect, rather than the physical dose, of radiotherapy we deliver to our patients, and establishes the first clinically-validated approach to genomic-based radiation oncology.

We have demonstrated that GARD is a critical parameter in understanding the impact of RT dose on clinical outcome. Whereas clinical trials of RT dose escalation in unselected patients have not shown to improve overall survival, here we demonstrate that the biologic effect induced by RT dose, as measured by GARD, is a powerful pan-cancer predictor of outcome. Thus, it is critical to shift the radiotherapy dosing paradigm from one that is based on physical dose to one that is based on biological effect in RT dose as measured by GARD.

Radiation oncology has a long history of updating its paradigms as new information becomes available. The integration of 3D anatomy into radiation treatment planning systems brought about by the invention of the CT scanner enabled the shift from one-size-fits-all radiotherapy field shapes to ones that are anatomically personalized. Similarly, now that it is possible to measure the biologic effect of RT dose, we propose the field can now move away from the empiric one-size-fits-all RT dose paradigm to one where dose is based on genomics and personalized.

Recently, multiple phase 3 randomized clinical trials failed to demonstrate improvements in clinical outcome after uniform dose escalation in multiple disease sites. How do you reconcile the results of these trials with the proposal that each unit increase in GARD positively impacts clinical outcome? While this stands in contrast to the recent trials of dose-escalation in unselected cohorts, it is not dissonant. While each unit increase in GARD is linearly associated with improved outcome in this large pooled analysis, the non-normal (often bimodal) GARD distributions in each disease site we observed previously[15], that together with increasing toxicity[23] this can lead to ranges of over which the the opportunity for clinical gain is so minimal as to not be noticed in trials powered for different assumptions. Taken together with our recent efforts to combine GARD with normal tissue complication probability, this allows for dose escalation to fail in select cohorts and dose levels[23]. In other words, GARD is at the individual patient level while physical dose escalation is looking at groups of patients. A GARD approach does not assume that all patients will benefit from dose escalation. Rather, it tells us which patients should.

Today, radiation therapy is prescribed using an empirically derived, one-size-fits-all approach, a paradigm in which patients with a given cancer type receive uniform doses of RT. This pooled analysis demonstrates that GARD, a measure of the biological effect of RT dose, is a continuous predictor of both recurrence and survival in RT-treated patients. We postulate that a GARD-based framework of RT should be adopted as the new paradigm for trial design and radiation dosing.

References

1. Abazeed, M. E. *et al.* Integrative radiogenomic profiling of squamous cell lung cancer. *Cancer research* **73**, 6289–6298 (2013).

2. Yard, B. D. *et al.* A genetic basis for the variation in the vulnerability of cancer to dna damage. *Nature communications* **7**, 1–14 (2016).

3. Pitter, K. L. *et al.* Pathogenic atm mutations in cancer and a genetic basis for radiotherapeutic efficacy. *JNCI: Journal of the National Cancer Institute* (2020).

4. Marcar, L. *et al.* Acquired resistance of egfr-mutated lung cancer to tyrosine kinase inhibitor treatment promotes parp inhibitor sensitivity. *Cell reports* **27**, 3422–3432 (2019).

5. Lou, B. *et al.* An image-based deep learning framework for individualising radiotherapy dose: a retrospective analysis of outcome prediction. *The Lancet Digital Health* **1**, e136–e147 (2019).

6. Eschrich, S. *et al.* Systems biology modeling of the radiation sensitivity network: a biomarker discovery platform. *International Journal of Radiation Oncology* Biology* Physics* **75**, 497–505 (2009).

7. Eschrich, S. A. *et al.* A gene expression model of intrinsic tumor radiosensitivity: prediction of response and prognosis after chemoradiation. *International Journal of Radiation Oncology* Biology* Physics* **75**, 489–496 (2009).

8. Ahmed, K. A. *et al.* The radiosensitivity index predicts for overall survival in glioblastoma. *Oncotarget* **6**, 34414–34422 (2015).

9. Ahmed, K. A. *et al.* Differences between colon cancer primaries and metastases using a molecular assay for tumor radiation sensitivity suggest implications for potential oligometastatic sbrt patient selection. *Int J Radiat Oncol Biol Phys* (2015). URL http://www.ncbi.nlm.nih.gov/pubmed/25838188. DOI 10.1016/j.ijrobp.2015.01.036.

10. Ahmed, K. *et al.* Radiosensitivity differences between liver metastases based on primary histology suggest implications for clinical outcomes following sbrt. *Int J Radiat Oncol Biol Phys* In press (2016).

11. Ahmed, K. A. *et al.* Radiosensitivity of lung metastases by primary histology and implications for stereotactic body radiation therapy using the genomically adjusted radiation dose. *J Thorac Oncol* **13**, 1121–1127 (2018). URL https://www.ncbi.nlm.nih.gov/pubmed/29733909. DOI 10.1016/j.jtho.2018.04.027.

12. Eschrich, S. A. *et al.* Validation of a radiosensitivity molecular signature in breast cancer. *Clinical Cancer Research* **18**, 5134–5143 (2012).

13. Torres-Roca, J. F. *et al.* Integration of a radiosensitivity molecular signature into the assessment of local recurrence risk in breast cancer. *International Journal of Radiation Oncology* Biology* Physics* **93**, 631–638 (2015).

14. Strom, T. *et al.* Radiosensitivity index predicts for survival with adjuvant radiation in resectable pancreatic cancer. *Radiotherapy and Oncology* **117**, 159–164 (2015).

15. Scott, J. G. *et al.* A genome-based model for adjusting radiotherapy dose (gard): a retrospective, cohort-based study. *The Lancet Oncology* **18**, 202–211 (2017).

16. Strom, T. *et al.* Regional radiation therapy impacts outcome for node-positive cutaneous melanoma. *J Natl Compr Canc Netw* **15**, 473–482 (2017). URL https://www.ncbi.nlm.nih.gov/pubmed/28404758.

17. Sjöström, M. *et al.* Identification and validation of single-sample breast cancer radiosensitivity gene expression predictors. *Breast Cancer Research* **20**, 64 (2018).

18. Locati, L. D. *et al.* Mining of self-organizing map gene-expression portraits reveals prognostic stratification of hpv-positive head and neck squamous cell carcinoma. *Cancers* **11**, 1057 (2019).

19. Mohammadi, H. *et al.* Using the radiosensitivity index (rsi) to predict pelvic failure in endometrial cancer treated with adjuvant radiation therapy. *International Journal of Radiation Oncology* Biology* Physics* **106**, 496–502 (2020).

20. Hall, E. J. & Giaccia, A. J. *Radiobiology for the Radiologist*, vol. 6 (Lippincott Williams & Wilkins, 2006).

21. Harrell Jr, F. E. *Regression modeling strategies: with applications to linear models, logistic and ordinal regression, and survival analysis* (Springer, 2015).

22. Ahmed, K. A. *et al.* Utilizing the genomically adjusted radiation dose (gard) to personalize adjuvant radiotherapy in triple negative breast cancer management. *EBioMedicine* **47**, 163–169 (2019).

23. Scott, J. G. *et al.* Personalizing radiotherapy prescription dose using genomic markers of radiosensitivity and normal tissue toxicity in non-small cell lung cancer. *Journal of Thoracic Oncology* (2020).

Supplementary Information

Code and data availability

All code and data for the analyses in this paper can be found on Github.

Basic statistics for included cohorts

Table 2. Percent of patients with recurrence free survival at 1 and 5 years, with and without radiation treatment.

	1-yr	1-yr	5-yr	5-yr
Site	+XRT	-XRT	+XRT	-XRT
Breast	0.968	0.952	0.708	0.806
TNBC	0.902	NA	0.754	NA
Endometrium	0.968	0.963	0.768	0.924
Head and Neck	0.741	NA	0.618	NA
NSCLC	0.809	NA	0.534	NA

Table 3. Percent of patients surviving at 1- and 5-years, with and without radiation treatment

	1-yr	1-yr	5-yr	5-yr
Site	+XRT	-XRT	+XRT	-XRT
Breast	0.99	0.95	0.81	0.747
TNBC	1.00	NA	0.88	NA
Endometrium	0.94	0.967	0.53	0.774
Glioma	0.70	0.054	0.05	0.00
NSCLC	0.88	NA	0.43	NA
Pancreas	0.77	0.8	0.35	0.279